DNA DNA DNA DNA 83.3%,99.9%; 75.0%(9/12),99.5%(11/21); 91.7%(11/12), 99.95% [

Similar documents
Explanation of your PAP smear

Management of Abnormal Pap Smear Clinical Practice Guideline

The society for lower genital tract disorders since 1964.

PROPERTY OF ELSEVIER SAMPLE CONTENT - NOT FINAL ABNORMAL PAP SMEAR (ABNORMAL CERVICAL CYTOLOGIC FINDINGS) Kathleen Dor

Cervical Cancer Screening Guideline

Sage Screening Program. Provider Manual

HPV OncoTect E6, E7 mrna Kit A highly specific molecular test for early detection of cervical cancer

Testing for HPV as an Objective Measure for Quality Assurance in Gynecologic Cytology

Cervical Cancer Screening and Management Guidelines: Changing Again, Huh?

HUMAN PAPILLOMAVIRUS (HPV) TESTING

Management of Abnormal PAP Smears. K Chacko, MD, FACP 2010 GIM Conference

Pap smears, cytology and CCHC lab work and follow up

ALABAMA BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM PROVIDER MANUAL

NATIONAL GUIDELINE FOR CERVICAL CANCER SCREENING PROGRAMME

Cervical Cancer Screening. Clinical Practice Guidelines for Average Risk Women

XI International Workshop of Lower Genital Tract Pathology HPV Disease: The global battle Rome April 2012

Cervical Cancer Screening

GUIDELINE DOCUMENT CERVICAL CANCER SCREENING IN SOUTH AFRICA 2015

The Cervical Screening Manual

Breast and Cervical Cancer Treatment Program (BCCTP) Application Guide

GLOBAL CONCERNS ABOUT HPV VACCINES FACT SHEET

Biomedical Engineering for Global Health. Lecture Thirteen

Cervical Screening and HPV Vaccine Guidelines In Saudi Arabia. Prof. Mohammed Addar Chairmen Gyneoncology section KKUH, King Saud University

Understanding. Cervical Changes A Health Guide for Women. National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Cervical Cancer Screening

The Pap Smear: Guidelines for Screening and Follow-up

FocalPoint guided screening

HPV and the Future of Cervical Screening

Nicole Kounalakis, MD

Protocol for an integrated data request of test results from the laboratories of pathological anatomy. SNOMED 3.5VF - users version January 2016

Original Articles. The Pittsburgh Cervical Cancer Screening Model. A Risk Assessment Tool

HPV testing in the follow-up of women post colposcopy treatment

Cervical Cancer Prevention and Early Detection What is cervical cancer?

Colposcopic Management of Abnormal Cervical Cytology and Histology

Cervical Screening Programme

MEDICAL POLICY SUBJECT: MOLECULAR MARKERS IN FINE NEEDLE ASPIRATES OF THE THYROID EFFECTIVE DATE: 11/19/15

HPV, Cervical Dysplasia and Cancer

The Diagnosis of Cancer in the Pathology Laboratory

2012 Updated Consensus Guidelines for the Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors

Cancer of the Cervix

Liquid-based cytology

Abnormal Pap Smear Tracking in General Internal Medicine Clinic

Screening for Cancer of the Cervix

Provider Reimbursement for Women's Cancer Screening Program

Making Sense of Your Pap and HPV Test Results

Il percorso diagnostico del nodulo tiroideo: il ruolo dell analisi molecolare

LDMAS (LOH Data Management and Analysis Software) User Guide

Changes in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain

Lung Carcinomas New 2015 WHO Classification. Spasenija Savic Pathology

SCREENING FOR CANCER OF THE CERVIX

Cervical cancer in 2 women with a Mirena : a pitfall in the assessment of irregular bleeding

HUMAN PAPILLOMAVIRUS (HPV) FACT SHEET

NHS Cervical Screening Programme Achievable standards, Benchmarks for reporting, and Criteria for evaluating cervical cytopathology

NHS Cervical Screening Having a colposcopy

Medicaid Family Planning Waiver Services CPT Codes and ICD-10 Diagnosis Codes

American Academy of Family Physicians

Should I Continue Having Mammograms to Screen for Breast Cancer? A decision aid for women aged 70 and older at their next screening mammogram.

CERVICAL CHANGES UNDERSTANDING A HEALTH GUIDE FOR WOMEN. family EDUCATION PATIENT. National Institutes of Health National Cancer Institute

The Role of the Pap Smear Diagnosis: Atypical Glandular Cells (AGC)

An abnormal Pap smear - what does it mean?

Appendix 1. HPVTest of Cure Management

The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion

Validation of BRAF Mutational Analysis in Thyroid Fine Needle Aspirations: A Morphologic- Molecular Approach

Office Visits. Breast

Cervical Cancer Prevention in Saudi Arabia: It is Time to Call for Action!

Cervical cancer screening: state of the art Victor M. Valdespino a,b and Victor E. Valdespino c

European Federation of Cytology Societies 4th Annual Tutorial in Cytopathology Trieste, Italy Monday 6th to Friday 10th June 2011

Pre test Question 2. Emily D. Babcock, DHSc, PA C, DFAAPA CAPA Annual Conference Palm Springs, California October 4, 2013

Background CA CANCER J CLIN 2012;62: VOLUME 62 _ NUMBER 3 _ MAY/JUNE

Why I don t recommend endometrial ablation

Conflict of Interest. Overdiagnosis. Beyond Bethesda: Challenges with Indeterminate Thyroid Aspirates 4/17/2015. Jeffrey F.

CXCA-MSP. The next step in cervical cancer prevention! GynTect : Epigenetic biomarkers for reliable cancer diagnostics.

Cervical cancer screening with the HPV test and the Pap test in women ages 30 and older

P ROGRAMMATIC G UIDELINES FOR S CREENING FOR C ANCER OF THE C ERVIX I N C ANADA

biopsy specimens of the breast

Accent on Health Obgyn, PC HPV Frequently Asked Questions

Medicaid Family Planning Waiver Services CPT Codes and ICD-9 Diagnosis Codes

Evaluation of HPV-16 and HPV-18 Genotyping for the Triage of Women With High-Risk HPV+ Cytology- Negative Results

IMMEDIATE HOT LINE: Effective March 2, 2015

Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) (908)

worry When to Cervical Abnormalities CME Workshop What s the situation? What are the trends? By Dianne Miller, MD, FRCSC In this article:

Cervical Cancer The Importance of Cervical Screening and Vaccination

Liquid-based cytology is an alternative technique

A Statistical Analysis of Rescreening Alarms

What is neuroendocrine cervical cancer?

EIN. (Endometrial Intraepithelial Neoplasia): Improved Criteria for diagnosing endometrial precancer. Stanley J. Robboy, MD, FCAP,

Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds

<1 cm WDT-UMP, FT-UMP. Kakudo K et al, Pathol Int,2009, Endocr J, 2011 and Pathol Int, 2012

The Role of Genetic Testing in the Evaluation of Thyroid Nodules. Thyroid Cancer and FNA. Thyroid Cancer. Pure Follicular Cancers.

Further investigations, treatments and new technologies

Curriculum Vitæ PROFESSIONAL RECORD

Pap Smears: A review of what s new. The Pap smear has been touted as the greatest. Is there a problem? Review of events

Request for Applications

Routine Vaginal Cuff Smear Testing in Post Hysterectomy Patients With Benign Uterine Conditions: When Is It Indicated?

Breast Fine Needle Aspiration Cytology Reporting : A Study of Application of Probabilistic Approach

Ulcerative colitis patients with low grade dysplasia should undergo frequent surveillance colonoscopies

Genital Human Papillomavirus. Patti E. Gravitt, PhD Johns Hopkins University

OBJECTIVES By the end of this segment, the community participant will be able to:

Cervical Cancer Screening: American College of Preventive Medicine Practice Policy Statement

Towards a single cell cancer diagnosis. Multimodal and Monocellular Measurements of Markers and Morphology (5M)

Transcription:

DNA (. 9;. ( ) 66) : [ ] DNA [ ] 7 9 6 DNA DNA [ ] 8 DNA 8.%99.9%; 7.%(9/)99.%(/); 9.7%(/) 99.9% [ ] DNA : DNA ; ; :R77. :A :-()7-9- S tu dy of th e Applica tion of DNA-im a ge -cytom e try (DNA-ICM) a n d Cytology for Ce rvica l Ca n ce r S cre e n in g SHEN Nia n-c hun ZHU C he n-ya n ZHANG He e t a l. (.Fa mily Pla nning Se rvic e Ce nte r of Zhuha izhuha i 9 China ;. Motic (Xia m e n ) Me d - ic a l Dia g nostic Ce nte rxia me n 66 China ) Abstract: [Purpose ] To investigate the value of DNA-image-cytometry (DNA-ICM) and conventional cytology in the cervical cancer screening. [Methods ] Two thousand one hundred and six women undergoing cervical cytological examination in Zhuhai Family Planning Service Center during Jan. 7 to Dec. 9 were enrolled in the study. Every sample was detected by both DNA-ICM and conventional cytology. Biopsy was taken if positive result was found and pathology of colposcopic biopsy was considered as golden standard. The relative sensitivity relative specificity positive predictive value (PPV) and negative predictive value (NPV) of DNA-ICM conventional cytology and combining both of them were calculated. [Results ] Two thousand and eighty-three samples were satisfactory. Of the cases recommended for biopsy had pathological diagnosis and follow-up. Relative sensitivity and relative specificity were 8.% and 99.9% of DNA-ICM; 7.% and 99.% of coventional cytology; 9.7% and 99.% combination of the two tests respectively. [Conclusion] Being compared with conventional cytology DNA-ICM has the higher sensitivity on detection of the cervical cancer and pre-cancerous lesions with no less specificity. If DNA-ICM was combined with conventional cytology the sensitivity of the test will be improved. Key words: DNA cytometry; cytology ; cervical cancer; screening : :--; :--8 : (97) : E-mail: julia8@hotmail.com [] [] 7 China CancerVol.No.7 9

. 7 9 / (intergrated optical density 9~ IOD) IOD 68 7.7. DI. ( %~% )~6 DI. % [] : (DI.) DNA DNA Feulgen DI. DNA DNA. : DNA : DNA Feulgen MotiCytometer (NCI) TBS (The Bethesda (System) (within normal limitswnl) ) (atypical squamous cells of unde- significanceasc-us) DNA terminied (atypical squamous cell-can- MotiCytometer not exclude HSILASC-H) 8 (low grade squa- mous intraepithelical lesion LSIL) (high grade squamous intraepithelical lesionhsil) (squa- mous cell carcinomascc) (atypical DNA (DNA indexdi) glandular cells of undetermined- : DNA significaneagus) (adeno- (DI=±.) carcinomaac) (.<DI<.) : (DI.) MotiCytometer TBS ASC-H LSIL DNA HSIL/CIS SCCAGUS AC;DNA : DI. ~ DI. % ; ( % DNA ) ~ : 7 China CancerVol.No.7

DNA % 8.6% TBS : DNA 7.% CIN CIN CIN(ROC.9() 99.% ) CIN. 9% 7.% 78.6% TBS. (P=.). TBS TBS TBS ROC ROC ROC.87() SPSS 6. DNA TBS ASC-H ASCUS NILM 6 DNA + /- DNA TBS CIN) (. DNA 8 DNA ;. DNA.8 DNA.6 ASCUS DNA ~. DNA. DNA DNA 8.% 99.% 8 DNA CIN/CIS CIN CIN + 9 /- 6 CIN/CIS CIN CIN. DNA +TBS + /- TBS + /- 9 9 8 6...6.8. - DNA ROC 7 China CancerVol.No.7

DNA 9.%. 9% 8% ROC DNA+TBS (P =.9 ( ) DNA + /-.) TBS CIN/CIS CIN CIN 8.. 9% (P=.) 9.7% 99.%..8.6....8.6.....6.8. - TBS ROC...6.8. - DNA+TBS ROC %~% [] [6] DNA [7] DNA [8~] DNA DNA ASC-H DNA ( 7 China CancerVol.No.7

and accuracy in liquid-based versus ) conventional cytology: a systematic review[j]. Lancet 6 67(): -. TBS [] Solomon D DaveyD Kurman R CIN et al. The Bethesda System: terminology for reporting results of cervical 7.%(9/) cytology[j]. JAMA 87(6): - DNA 9. 8.% [] Remmerbach T Weidenbach H Pomjanski N et al. Cytologic and DNAcytometric ( 99.%) early diagnosis of oral cancer DNA [J]. Anal Cell Pathol l (): -. DNA [6] Obwegeser J Schneider V. Thinlayer cervical cytology: a new meta-anal- ysis[j]. Lancet 6 67(): 88-89. [7] Sudbo J Reith A. The evolution of ROC predictive oncology and molecular-based therapy for oral cancer prevention[j]. Int J Cancer : 9-. DNA [8] Azúa J Romeo P Morales M et al. DNA quantification as a prognostic factor in gastric adenocarcinoma [J]. Anal : TBS Quant Cytol Histol 998():-. DNA []. (ACCP) [9] Dey P Luthra UK Prasad A et al. TBS Cytologic grading and DNA image cytomelry of breast carcinoma on fine nee- DNA [J]. 9 69(): 7. dle aspiration cytology smear [J]. Anal [] Benedet JL Anderson GH. Cervical Quant Cytol Histol 999 (): 7-. intraepithelial neoplasia (9.7% ) in British [] Anderson G MacAulay CF Matisic J et al. The use of an automated Columbia: a comprehensive program for (99.%) ROC detection diagnosis and treatment [J]. image cytometer for screening and quantitative assessment of cervical lesions for Gynecol Oncol 98 : s8-9. [] Davey E Barratt A Irwig L et al. screening. Columbia Cervical Smear Effect of study design and quality on unsatisfactory rates cytology classification Screening Programme [J]. Cytopathology 997 8(): 98-. 7 China CancerVol.No.7